阿拉丁(688179.SH):擬取得雅酶生物25%股權
格隆匯4月22日丨阿拉丁(688179.SH)公佈,公司擬以增資、認購老股方式對上海雅酶生物醫藥科技有限公司(簡稱“目標公司”或“雅酶生物”)進行投資,認購目標公司一定的新增註冊資本及認購老股。本次投資分兩步走,第一步由公司先按14,000萬元的估值向目標公司增資2,470萬元,取得目標公司增資後15%的股權;第二步由公司按16,470萬元的估值受讓原股東持有的目標公司(增資後)10%的股權,股權轉讓總對價為1,647萬元。本次投資下投資方合計出資4,117萬元。上述資金來自公司自籌資金。本次投資完成後,公司將持有雅酶生物25%的股權。
公司本次擬對外投資的目標公司上海雅酶生物醫藥科技有限公司是一家專注於生命科學領域科研工具產品的研發生產型企業,業務範圍包括抗體、蛋白試劑以及細胞生物學產品等,尤其是在蛋白免疫印跡方向的整體解決方案方面具有獨特優勢,產品包括蛋白提取、蛋白定量、電泳、轉膜、抗體、化學發光全線試劑以及電泳設備等。與阿拉丁抗體、蛋白、生化試劑產品形成強有力的互補,形成生物實驗的全線整體解決方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.